✦ LIBER ✦

Cost-Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China

✍ Scribed by Li Yang; Ming Li; Li-bo Tao; Mingliang Zhang; M. Deborah Nicholl; Peng Dong

Book ID: 109079082
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 63 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2009.00630.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of switching to long-acting inje

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia

✍ Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Seung-Hyun Lee; Yo-Han Lee; Su-Jin Yang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral

Remission in schizophrenia: one-year Ita

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac

Safety and efficacy of long-acting injec

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients

✍ Swapna Verma; Mythily Subramaniam; Edimansyah Abdin; Kang Sim; Alex Su; Nelson L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders. Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior or

Comparison of metabolic changes in patie

Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine

✍ David P. McDonnell; Ludmila A. Kryzhanovskaya; Fangyi Zhao; Holland C. Detke; Pe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 1 views

Metabolic changes were examined in patients with schizophrenia during treatment with either oral olanzapine or olanzapine long‐acting injection (LAI). Data were collected from patients who had been stabilized on oral olanzapine (10, 15, or 20 mg/day) for ≥4 weeks and then randomized to either contin

The impact upon extra-pyramidal side eff

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia

✍ C. W. Ritchie; E. Chiu; S. Harrigan; K. Hall; A. Hassett; S. Macfarlane; M. Mast 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Abstract ## Background Atypical antipsychotics are commonly used in the management of schizophrenia in late life with evidence suggesting they induce lower rates of motor disturbance, but have similar efficacy to conventional antipsychotics. Trials in the elderly have been either retrospective,